**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 90628

**Manuscript Type:** ORIGINAL ARTICLE

***Clinical and Translational Research***

**Serum urate is associated with an increased risk of inflammatory bowel disease: A bidirectional Mendelian randomization study**

Zhang S *et al*. MR for urate levels and IBD

Song Zhang, Xue Fang, Le Kang, Xiang-Yu Sui, Miao Liu, Yu-Jia Luo, Shuo Fu, Zhao-Shen Li, Sheng-Bing Zhao, Yu Bai

**Song Zhang, Xue Fang, Le Kang, Xiang-Yu Sui, Miao Liu, Yu-Jia Luo, Shuo Fu, Yu Bai,** Department of Gastroenterology, Changhai Hospital, Shanghai 200433, China

**Zhao-Shen Li, Sheng-Bing Zhao,** Department of Gastroenterology, Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai 200433, China

**Zhao-Shen Li, Sheng-Bing Zhao,** Digestive Endoscopy Center, Changhai Hospital, Naval/Second Military Medical University, Shanghai 200433, China

**Zhao-Shen Li, Sheng-Bing Zhao,** National Clinical Research Center for Digestive Diseases, Shanghai 200433, China

**Co-first authors:** Song Zhang and Xue Fang.

**Co-corresponding authors:** Sheng-Bing Zhao andYu Bai.

**Author contributions:** Zhang S, Zhao SB and Bai Y designed the research; Zhang S, Kang L and Luo YJ performed the research; Zhang S, Fang X, Kang L and Luo YJ analyzed the data; Sui XY, Liu M and Fu S visualized the data; Zhang S, Fang X, Kang L, Sui XY, Zhao SB and Bai Y wrote the paper; Fang X, Zhao S and Bai Y received the funding; Li ZS, Zhao SB and Bai Y supervised the research.

**Supported by** National Natural Science Foundation of China, No. 82170567, No. 81873546, No. 82170568, and No. 82300627; Program of Shanghai Academic/Technology Research Leader, No. 22XD1425000; The "Shu Guang" project of Shanghai Municipal Education Commission and Shanghai Education Development Foundation, No. 19SG30, China; Deep Blue Project of Naval Medical University (Pilot Talent Plan); The Chenguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission, No. 22CGA42; The Shanghai Sailing Program, No. 23YF1458600; and Shanghai Natural Science Foundation, No. 23ZR1478700.

**Corresponding author: Yu Bai, MD, PhD, Academic Research, Associate Professor, Researcher,** Department of Gastroenterology, Changhai Hospital, No. 168 Changhai Road, Yangpu District, Shanghai 200433, China. changhaibaiyu@smmu.edu.cn

**Received:** December 9, 2023

**Revised:** January 1, 2024

**Accepted:** January 23, 2024

**Published online:**

**Abstract**

BACKGROUND

Previous studies have indicated bidirectional associations between urate levels and inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). However, it remains unclear whether the observations are causal because of confounding factors.

AIM

To investigate the causal associations between urate levels and IBD using bidirectional Mendelian randomization (MR).

METHODS

Independent genetic variants for urate levels and IBD were selected as instrumental variables from published genome-wide association studies (GWASs). Summary statistics for instrument-outcome associations were retrieved from three separate databases for IBD (the UK Biobank, the FinnGen database and a large GWAS meta-analysis) and one for urate levels (a large GWAS meta-analysis). MR analyses included the inverse-variance-weighted method, weighted-median estimator, MR-Egger and sensitivity analyses (MR-PRESSO). A meta-analysis was also conducted to merge the data from separate outcome databases using a fixed-effects model.

RESULTS

Genetically higher serum urate levels were strongly associated with an increased risk of UC [odds ratio (OR): 1.95, 95% confidence interval (CI): 1.86-2.05] after outlier correction, and the ORs (95%CIs) for IBD and CD were 0.94 (95%CI: 0.86-1.03) and 0.91 (95%CI: 0.80-1.04), respectively. Animal studies have confirmed the positive association between urate levels and UC. Moreover, genetically predicted IBD was inversely related to urate levels (OR: 0.97, 95%CI: 0.94-0.99). However, no association was observed between genetically influenced UC or CD and urate levels.

CONCLUSION

Urate levels might be risk factors for UC, whereas genetically predicted IBD was inversely associated with urate levels. These findings provide essential new insight for treating and preventing IBD.

**Key Words:** Inflammatory bowel disease; Urate levels; Antioxidant; Mendelian randomization; Single nucleotide polymorphism

Zhang S, Fang X, Kang L, Sui XY, Liu M, Luo YJ, Fu S, Li ZS, Zhao SB, Bai Y. Serum urate is associated with an increased risk of inflammatory bowel disease: A bidirectional Mendelian randomization study. *World J Clin Cases* 2024; In press

**Core Tip:** Previous observational studies have indicated the association between urate levels and inflammatory bowel disease (IBD) (including ulcerative colitis (UC) and Crohn’s disease). To overcome the limitations of conventional observational studies and investigate the causal association between urate levels and IBD, we conducted a bidirectional Mendelian randomization (MR) study. MR analysis revealed that higher urate levels may be risk factors for UC, and genetically predicted IBD was inversely associated with urate levels.

**INTRODUCTION**

Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn’s disease (CD), is characterized by chronic inflammation and a prolonged duration in the gastrointestinal tract[1]. Epidemiological studies have confirmed that the incidence of IBD in developing countries has exceeded 0.3% with the rapid adoption of the Western lifestyle[1,2]. Specifically, there are 322 and 214 cases per 100000 for CD and 505 and 214 cases per 100000 for UC in Europe and the United States, respectively. The long course of IBD lasts throughout the patient’s life, and the risk of colorectal cancer is much greater than that in the general population[3,4]. The pathogenesis of IBD involves interplay between environmental risk factors (not limited to smoking, unfavorable lifestyles and diets) and genetic variants, resulting in inadequate intestinal immune activation and dysbiosis of the gut microbiota[5,6]. Previous studies demonstrated that depleted mucosal antioxidant defense was common in IBD and thus may impede mucosal repair and compromise the inflamed mucosa[7]. Over the past decade, the association between antioxidants and IBD has attracted considerable interest[7-10] in light of the strong association between antioxidant capacity and the severity and disease activity of IBD.

Urate is vital as an antioxidant for neutralizing hydroxyl, superoxide and peroxynitrite radicals, which can decrease oxidative stress *in vivo*[11,12]. Previous studies have indicated that the serum uric acid-to-creatinine ratio is positively correlated with disease activity in CD patients[13]. Increased urate levels were positively correlated with an increased risk of UC[14]. Moreover, the use of a clinical drug (allopurinol) improved the severity of colitis by reducing urate levels[15]. An animal study by Rahimian *et al*[9] further demonstrated that uric acid mediated the protective effects of inosine against colitis. Overall, the relationship between urate levels and IBD (including UC and CD) has not been well established. A recent Mendelian randomization (MR) study by Chen *et al*[16] did not support the causal effect of serum urate levels on UC or CD incidence. However, the causal effect of these polymorphisms remains elusive because of the limited number of single-nucleotide polymorphisms (SNPs) used as instrumental variables (IVs). However, the causal effect of IBD (including UC and CD) on urate levels remains unclear.

Using genetic variants identified through genome-wide association studies (GWAS), MR is a popular approach for investigating the causal relationship between exposures and outcomes[17]. Therefore, to overcome the limitations of conventional observational studies, we aimed to examine the potential bidirectional relationship between IBD (including UC and CD) and serum urate levels in the present MR study. In addition, we conducted *in vivo* animal studies to verify the association between urate levels and IBD. This study provides reliable insight into the causal associations between urate levels and IBD.

**MATERIALS AND METHODS**

***Study design***

A bidirectional two-sample MR analysis was performed to assess the causal relationship between IBD and urate levels (Figure 1). SNPs associated with risk factors were selected as IVs. The MR study was based on three assumptions: (1) The SNPs used as IVs are strongly associated with exposure (urate level or IBD); (2) The SNPs are not associated with any confounder of exposure–outcome associations; and (3) The SNPs exert effects through exposure only. In combination with the three principles mentioned above, palindromic SNPs were identified and excluded in IV selection. All the data used in the current study were publicly available GWAS summary statistics; therefore, no additional ethical approval or informed consent was needed. GWAS summary statistics were searched to extract leading SNPs related to urate levels and IBD (including UC and CD) as IVs. Gene-outcome associations were retrieved from three databases: (1) A large-scale GWAS meta-analysis; (2) The Finngen database (version 7, https://r7.finngen.fi/); and (3) The UK Biobank (UKB).

***Selection of the instrumental genetic variables***

SNPs related to urate levels were selected as IVs from a GWAS (Köttgen *et al*[18]), which included a total sample size of 110347 European individuals with various serum urate levels[18]. SNPs that were significantly associated with urate levels (*P* < 5 × 10-8) were extracted. A linkage disequilibrium (LD)-based clumping procedure was performed using the 1000 Genomes EUR reference panel (r2 < 0.01 and clump distance > 10000 kb) to ensure that each IV was independent. When SNPs related to exposure were absent in the outcome GWAS statistics, the proxy SNPs significantly associated with the variants of interest were selected (r2 > 0.8).

Summary statistics for IBD were obtained from the GWAS meta-analysis (Liu *et al*[19]), which included a total of 34652 participants of European ancestry (cases/controls for IBD: 12882/21770; UCs: 6968/20464; CDs: 5956/14927). Nearly 12 million SNPs were included in all three GWAS summary statistics. SNPs (*P* < 5 × 10-8) were selected and used for LD-based clumping. The proxy SNPs were extracted when SNPs related to exposure were absent. The IV selection procedure for IBD was the same as that for urate levels (described in the previous paragraph).

F-statistics, calculated as (beta/SE)2, were used to quantify the strength of each IV, and a value > 10 was considered sufficient[20]. In the present study, all F-statistics were greater than 10, indicating that there is little possibility of weak instrument bias based on summary statistics.

***SNP-outcome data sources***

Summary-level data for urate levels were obtained from GWAS statistics (Köttgen *et al*[18]), as described in section 2.2. Gene-environment associations for IBD were obtained from three separate databases: (1) The GWAS meta-analysis from Liu *et al*[19]; (2) The Finngen database; and (3) The UKB (for UC data only). The Liu *et al*’s study has been described previously[19]. In the Finngen study, CD and UC were defined by their ICD codes, while IBD was a term consisting of CD, UC and indeterminate colitis. Among the patients and controls, 8966/312336 had IBD, 3243/318059 had CD, and 6803/314499 had UC. The UKB data for UC were extracted from a GWAS meta-analysis by Jiang *et al*[21], which included 2569 patients and 453779 controls. GWASs on IBD and CD were not available in the UKB.

***Statistical analysis of primary MR***

The primary analysis method employed was the inverse-variance weighted (IVW) method, which assumes that all SNPs are valid and yields the most precise estimates[22]. In the presence of a sufficient sample size and absence of the pleiotropic effect of IVs, the IVW estimate is robust to confounding factors and approximates the true value[23]. A multiplicative random effect IVW model was applied when the heterogeneity significantly differed (*P* < 0.05).

***Supplementary and sensitivity analysis***

In addition to the IVW method, other robust methods (weighted median, MR-Egger and MR-PRESSO) were used to ensure the consistency and efficiency of the MR results. The weighted-median method could provide consistent causal estimates even when more than half of the IVs were invalid[23]. The MR-Egger estimates allowed the included IVs to demonstrate unbalanced pleiotropy[24]. The MR-PRESSO approach was used to detect horizontal pleiotropic outliers[25], and IVW estimates were performed to further investigate the causal relationship between exposure and outcome through outlier removal. Cochran’s Q test was applied to further examine the heterogeneity among all SNPs within each database. Leave-one-out analyses and scatter plots describing the causal relationship between serum urate levels and IBD were also generated.

***Animal studies***

All animal experimental procedures were approved and conducted in accordance with the guidelines of the Animal Care Committee of Navy Medical University. C57BL/6 mice were kept under a 12-h light/dark cycle with free access to water and a standard rodent diet. Cohoused, seven-week-old male C57BL/6 mice (*n* = 5) were administered 2% dextran sulfate sodium (DSS) (36–50 kDa; MP Biomedicals) in their drinking water ad libitum for 7 consecutive days, followed by 2 d of normal water.

***Disease activity score and histological analysis in mice***

Body weight, the presence of occult bacteria per rectum, stool consistency, and colon length were documented. A scoring system was used to assess diarrhea and the presence of occult or overt blood in the stool. Changes in body weight are reported as the percentage loss of baseline body weight[26]. The ring of the rectum was harvested postmortem, fixed in 4% buffered formalin, and embedded in paraffin for subsequent HE staining.

***Enzyme-linked immunosorbent assay***

Interleukin (IL)-6, IL-1β, tumor necrosis factor (TNF)-α and urate levels in the serum were quantified using commercial Enzyme-linked immunosorbent assay (ELISA) kits in accordance with the manufacturer’s instructions (Multi Sciences Ltd., Hangzhou, China).

MR results are presented as odds ratios (ORs) with 95% confidence intervals (CIs) of the outcome risk of a unit change in exposure. A two-sided *P* value < 0.05 was considered to indicate statistical significance. All the statistical analyses were performed mainly with R software (version 4.2.0, The R Foundation for Statistical Computing; TwoSampleMR and MR-PRESSO package) and SPSS 26.0.

**RESULTS**

***Urate levels to IBD***

Twenty-seven independent SNPs were identified as genetic IVs for urate levels, and the median (minimum, maximum) F statistic was 63.4 (35.4-1406.3) (Supplementary Table 1). Detailed information for urate-related SNPs is listed in Supplementary Table 2.

According to the meta-analysis of IVW estimates, the pooled ORs for IBD, UC and CD that were genetically predicted per log-OR increase in urate levels were 0.94 (95%CI: 0.86-1.03), 0.97 (95%CI: 0.89-1.07) and 0.91 (95%CI: 0.80-1.04), respectively (Figure 2).

According to the sensitivity analysis (Supplementary Table 3), the three results were similar for the weighted-median estimator (Supplementary Figure 1). No pleiotropic effects were detected in any of the databases by MR-Egger estimation. Different outliers were identified by MR-PRESSO for IBD (*n* = 4), UC (*n* = 5) and CD (*n* = 5) in the GWAS meta-analysis by Liu *et al*[19] and UC (*n* = 3) in the UKB database, which resulted in potential pleiotropy assessed by global testing. Most of the results remained similar after outlier exclusion correction, except for IVs of urate levels on UC (UKB database) (before correction: OR = 0.93, 95%CI: 0.75-1.17; after correction: OR = 2.70, 95%CI: 2.54-2.87). Cochran’s Q test was performed after outlier exclusion to test heterogeneity. Among the urate level-related genetic IVs affecting IBD and CD identified by Liu *et al*[19] and UC (from the UKB database), a multiplicative random effect IVW model was used to evaluate the genetic estimate after heterogeneity was detected. A strongly positive causal relationship was detected between urate levels and UC after outlier exclusion and between urate levels and UC incidence according to a multiplicative random effects IVW estimate (OR = 1.95, 95%CI: 1.86-2.05). A scatter plot was generated to visualize the effect size of each MR method (Figure 3). Leave-one-out analysis indicated that the associations between urate levels and IBD incidence were unlikely to be driven by certain specific SNPs (Supplementary Figure 2).

***IBD-to-urate levels***

A total of 117, 87, and 60 SNPs reached a genome-wide level of significance with IBD, UC and CD, respectively. A summary and detailed description of the variants are presented in Supplementary Tables 1 and 4.

The results of IVW analysis demonstrated that IBD was negatively correlated with urate levels (OR = 0.97, 95%CI: 0.94-0.99) (Figure 4). However, no association between UC (or CD) and urate levels was observed. The combined ORs of UC and CD on urate levels were 0.99 (95%CI: 0.97-1.01) and 1.00 (95%CI: 0.99-1.02), respectively.

According to the sensitivity analysis (Supplementary Table 5), the weighted-median estimator showed comparable results to the estimates from the IVW analysis (Supplementary Figure 3). MR-Egger analysis demonstrated no evidence of pleiotropy, while the MR-PRESSO global test indicated that there were 7 outliers from the association between IBD and urate levels (*P* = 0.02) and 2 statistically nonsignificant outliers from the association between CD and urate levels (*P* = 0.006). Heterogeneity was detected from the association between IBD and urate levels after outlier correction by Cochran’s Q statistics. However, the results remained similar after correction for outliers and after the application of the multiplicative random effects IVW estimate (OR = 0.97, 95%CI: 0.94-0.99). A scatter plot was generated to visualize the effect size of each MR method (Figure 5). The results remained consistent in the leave-one-out analysis (Supplementary Figure 4), indicating that the results of the current analyses were stable and reliable.

***Results of animal studies, HE staining and ELISA***

To validate the positive association between serum urate levels and UC, 2% DSS was used to induce experimental colitis (*n* = 5 per group). The effects of these treatments included a decrease in body weight (Figure 6A), an increase in the disease activity index (Figure 6B), a decrease in colon length (Figure 6C), and increased inflammatory infiltration according to HE staining (Figure 6D). The expression levels of proinflammatory factors, including IL-6, IL-1β and TNF-α, in the serum were significantly elevated in IBD mice (Figure 6E). Additionally, the serum urate level was also increased in IBD mice (Figure 6F). Together, these results provide evidence that there is a positive association between urate levels and IBD.

**DISCUSSION**

In the current study, we evaluated the causal relationship between IBD and urate levels. We found evidence that genetic liability to urate levels was strongly associated with a higher risk of UC after outlier correction, and genetic liability to IBD was slightly anticorrelated to urate levels. Animal studies have confirmed the association between high urate levels and IBD. However, our study did not observe a causal relationship between CD and urate levels.

Previous observational studies have suggested that urate levels might be a risk factor for IBD. Zhu *et al*[13] included more than four hundred IBD patients and 51 non-IBD controls and reported that urate levels were significantly greater in IBD patients. Similarly, Tian *et al*[14] reported that increased urate levels were associated with UC in a retrospective case-control study. Moreover, IBD patients have an increased incidence of nephrolithiasis as well as urolithiasis[27]. To date, the only MR analysis conducted to investigate the causal relationship of urate levels with IBD has demonstrated that genetically predicted urate levels are not associated with the risk of CD or UC. In part, our study was consistent with previous reports in that we found a strong positive association between urate levels and UC but not with CD or IBD. Animal studies further demonstrated a positive association between urate levels and colitis incidence. In addition, IBD but not UC or CD was inversely correlated with urate levels.

The biological connection between IBD and urate levels has not been fully elucidated. Current studies suggest that intestinal inflammation (including oxidative stress) and dysbiosis of the gut microbiota are the main etiologies of IBD[6]. Increased urate levels mediate the exacerbation of mucosal colitis induced by DSS by enhancing intestinal permeability[15]. Treatment with allopurinol via gavage alleviated the pathogenic increase in proinflammatory cytokines and reduced oxidative stress biomarkers in patients with colitis[15,28]. A recent study reported that rhein significantly alleviated DSS-induced colitis and led to decreased urate levels, while the probiotic Lactobacillus was involved in regulating host metabolism[29]. These results support the idea of a relationship between serum urate levels and intestinal inflammation, suggesting that urate levels might be a therapeutic target for IBD. Our results supported previous results that urate levels were positively associated with an increased risk of UC but not with IBD or CD. One of the reasons could be the lack of association between urate levels and CD (a major subtype of IBD). Our results also confirmed that there was no bidirectional causal relationship between urate levels and CD incidence. Furthermore, we considered only the dichotomous IBD diagnosis rather than the IBD course or severity, which greatly influenced patients’ clinical manifestations. Further MR analysis should be conducted to investigate the causal relationship between urate levels and disease activity and course of IBD, as relevant GWAS data are available. Moreover, we found a slight inverse association between IBD incidence and urate levels. One possible explanation could be that including summary statistics from only one GWAS increased the heterogeneity and reduced the credibility of our results. A meta-analysis should be conducted once multiple data sources for urate levels are available.

There are three major strengths in the current study. First, the MR design is suitable for causal inference. As an alternative to randomized controlled trials, the MR method can partly avoid bias from confounding factors and reverse causation, which might increase the reliability of the results compared with those of observational studies. To our knowledge, this is the first bidirectional MR analysis investigating the causal relationship between IBD (and its subtypes) and urate levels. Second, we obtained summary-level data from large genetic consortia and GWASs, which included large sample sizes, with 110347 participants for urate levels, 355952 (21846 patients) for IBD, 805082 (16340 patients) for UC and 342185 (9199 patients) for CD. Third, population stratification bias was minimized because all GWAS summary statistics data in the current study were generated from the European population.

Nevertheless, potential limitations in our MR study should be considered. First, MR design can be biased by pleiotropic effects. The current study involved the implementation of various sensitivity analyses, which were performed based on distinct assumptions regarding the fundamental characteristics of pleiotropy, and most of the analyses showed stable results. Moreover, MR-Egger tests and MR-PRESSO analyses were conducted to explore horizontal pleiotropy[24,25]. After removing potential outlier SNPs, we observed a strong positive causal relationship between urate levels and UC, and most of the results were robust. Second, all participants included in the current study were European, which may limit the generalizability of our findings to other populations. Further MR analyses should be conducted to verify our findings in individuals of non-European descent. Third, in our present research, summary statistics for IBD were obtained from three databases, while data on urate levels were sourced solely from one large GWAS meta-analysis (Köttgen *et al*[18]). The utilization of data from a single source may compromise the reliability of the results. Therefore, once GWAS summary statistics from diverse sources become available, meta-analyses should be conducted to further verify our findings on the inverse association between IBD and urate levels.

The findings that serum urate levels increase the risk of UC add to the evidence from another MR analysis demonstrating a new risk factor for IBD. Recently, a meta-analysis based on large-scale cohorts demonstrated that the consumption of several types of food and drinks, for example, beer, wine, and beef, was associated with increased serum urate levels[30]; however, we are unaware of the risk related to the foods mentioned above. Moreover, many dietary approaches have been developed to reduce inflammation, prevent relapse, and manage the disease severity of IBD[31]. Our current study indicated that monitoring and managing urate levels in patients with IBD and accounting for diets that are associated with elevated urate levels in dietary therapy may provide additional benefits.

**CONCLUSION**

In summary, we systemically evaluated the potential causal relationship between IBD and urate levels. Our current MR analysis demonstrated that genetically predicted urate levels are causally associated with an elevated risk of UC, while IBD was inversely correlated with urate levels. Considering the close relationship between diet and urate levels, our study provides crucial new insight into treating and preventing IBD. These findings indicate that IBD patients may benefit from monitoring and reducing their serum urate levels.

**ARTICLE HIGHLIGHTS**

***Research background***

Inflammatory bowel disease (IBD), mainly consisted of Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease. As a vital antioxidant, urate can decrease oxidative stress *in vivo*, which may be associated with IBD state. However, the causality between IBD and urate levels has not been investigated.

***Research motivation***

Previous studies indicated uric acid-to-creatinine ratio and urate were positively correlated with the disease activity of CD and UC. Despite the existing findings demonstrated the bidirectional associations between urate levels and IBD, including UC and CD, the causality association between them remains unclear. This study seeks to investigate the causal association between IBD and urate through Mendelian randomization (MR) study, which may shed crucial new insight into treating and preventing IBD. In specific, IBD patients may benefit from monitoring and reducing serum urate levels.

***Research objectives***

The study aims to investigate the bidirectional causal relationship between urate levels and IBD by performing MR analysis, to better understand the gene susceptibility of urate levels and IBD.

***Research methods***

Single nucleotide polymorphisms retrieved from genome-wide association studies (GWASs) was selected as instrument variants. Summary GWAS statistics for instrument-outcome associations were retrieved from three separate databases for IBD (UK Biobank, FinnGen database and a large GWAS meta-analysis) and one for urate levels (a large GWAS meta-analysis). Inverse-variance-weighted was performed to investigate the bidirectional causal relationship, and other sensitivity analysis were conducted to strengthen the results. Meta-analysis was conducted to merge the data from separate outcome databases using a fixed-effects model.

***Research results***

The current study found that the genetic susceptibility to urate levels was associated with increased UC risk [odds ratio (OR): 1.95, 95% confidence interval (CI): 1.86-2.05], and animal studies confirmed the positive association between urate levels and UC. Additionally, genetically predicted IBD was inversely related to urate levels (OR: 0.97, 95%CI: 0.94-0.99). However, no association was observed between genetically influenced UC or CD and urate levels.

***Research conclusions***

This study identified urate levels might be risk factors for UC, whereas genetically predicted IBD was inversely associated with urate levels. The current results shed new insight into prevention and treatment of IBD.

***Research perspectives***

Although the current study investigated the causal relationship between urate levels and UC, which was further verified by animal studies, the precise mechanism by which high urate levels affects the development of UC remains unknown. More basic and clinical studies should be conducted for identification of key regulators and molecules during the process.

**ACKNOWLEDGEMENTS**

We thank the UKB, the Finngen database and the IEU OpenGWAS project for sharing the summary-level data and all efforts from the researchers.

**REFERENCES**

1 **Khalili H**, Chan SSM, Lochhead P, Ananthakrishnan AN, Hart AR, Chan AT. The role of diet in the aetiopathogenesis of inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol* 2018; **15**: 525-535 [PMID: 29789682 DOI: 10.1038/s41575-018-0022-9]

2 **Ng SC**, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* 2017; **390**: 2769-2778 [PMID: 29050646 DOI: 10.1016/S0140-6736(17)32448-0]

3 **Benchimol EI**, Guttmann A, Griffiths AM, Rabeneck L, Mack DR, Brill H, Howard J, Guan J, To T. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. *Gut* 2009; **58**: 1490-1497 [PMID: 19651626 DOI: 10.1136/gut.2009.188383]

4 **Frolkis AD**, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, Frolkis T, Barkema HW, Rioux KP, Panaccione R, Ghosh S, Wiebe S, Kaplan GG. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. *Gastroenterology* 2013; **145**: 996-1006 [PMID: 23896172 DOI: 10.1053/j.gastro.2013.07.041]

5 **Huang H**, Fang M, Jostins L, Umićević Mirkov M, Boucher G, Anderson CA, Andersen V, Cleynen I, Cortes A, Crins F, D'Amato M, Deffontaine V, Dmitrieva J, Docampo E, Elansary M, Farh KK, Franke A, Gori AS, Goyette P, Halfvarson J, Haritunians T, Knight J, Lawrance IC, Lees CW, Louis E, Mariman R, Meuwissen T, Mni M, Momozawa Y, Parkes M, Spain SL, Théâtre E, Trynka G, Satsangi J, van Sommeren S, Vermeire S, Xavier RJ; International Inflammatory Bowel Disease Genetics Consortium, Weersma RK, Duerr RH, Mathew CG, Rioux JD, McGovern DPB, Cho JH, Georges M, Daly MJ, Barrett JC. Fine-mapping inflammatory bowel disease loci to single-variant resolution. *Nature* 2017; **547**: 173-178 [PMID: 28658209 DOI: 10.1038/nature22969]

6 **Ni J**, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? *Nat Rev Gastroenterol Hepatol* 2017; **14**: 573-584 [PMID: 28743984 DOI: 10.1038/nrgastro.2017.88]

7 **Buffinton GD**, Doe WF. Depleted mucosal antioxidant defences in inflammatory bowel disease. *Free Radic Biol Med* 1995; **19**: 911-918 [PMID: 8582668 DOI: 10.1016/0891-5849(95)94362-h]

8 **Koutroubakis IE**, Malliaraki N, Dimoulios PD, Karmiris K, Castanas E, Kouroumalis EA. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. *Dig Dis Sci* 2004; **49**: 1433-1437 [PMID: 15481315 DOI: 10.1023/b:ddas.0000042242.22898.d9]

9 **Rahimian R**, Fakhfouri G, Daneshmand A, Mohammadi H, Bahremand A, Rasouli MR, Mousavizadeh K, Dehpour AR. Adenosine A2A receptors and uric acid mediate protective effects of inosine against TNBS-induced colitis in rats. *Eur J Pharmacol* 2010; **649**: 376-381 [PMID: 20868668 DOI: 10.1016/j.ejphar.2010.09.044]

10 **Bourgonje AR**, Feelisch M, Faber KN, Pasch A, Dijkstra G, van Goor H. Oxidative Stress and Redox-Modulating Therapeutics in Inflammatory Bowel Disease. *Trends Mol Med* 2020; **26**: 1034-1046 [PMID: 32620502 DOI: 10.1016/j.molmed.2020.06.006]

11 **Krishnan E**. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. *Rheumatology (Oxford)* 2010; **49**: 1229-1238 [PMID: 20202928 DOI: 10.1093/rheumatology/keq037]

12 **Waring WS**. Uric acid: an important antioxidant in acute ischaemic stroke. *QJM* 2002; **95**: 691-693 [PMID: 12324642 DOI: 10.1093/qjmed/95.10.691]

13 **Zhu F**, Feng D, Zhang T, Gu L, Zhu W, Guo Z, Li Y, Lu N, Gong J, Li N. Altered uric acid metabolism in isolated colonic Crohn's disease but not ulcerative colitis. *J Gastroenterol Hepatol* 2019; **34**: 154-161 [PMID: 29926959 DOI: 10.1111/jgh.14356]

14 **Tian S**, Li J, Li R, Liu Z, Dong W. Decreased Serum Bilirubin Levels and Increased Uric Acid Levels are Associated with Ulcerative Colitis. *Med Sci Monit* 2018; **24**: 6298-6304 [PMID: 30196310 DOI: 10.12659/MSM.909692]

15 **Chiaro TR**, Soto R, Zac Stephens W, Kubinak JL, Petersen C, Gogokhia L, Bell R, Delgado JC, Cox J, Voth W, Brown J, Stillman DJ, O'Connell RM, Tebo AE, Round JL. A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. *Sci Transl Med* 2017; **9** [PMID: 28275154 DOI: 10.1126/scitranslmed.aaf9044]

16 **Chen J**, Ruan X, Yuan S, Deng M, Zhang H, Sun J, Yu L, Satsangi J, Larsson SC, Therdoratou E, Wang X, Li X. Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study. *Aliment Pharmacol Ther* 2023; **57**: 399-408 [PMID: 36645152 DOI: 10.1111/apt.17392]

17 **Lawlor DA**, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med* 2008; **27**: 1133-1163 [PMID: 17886233 DOI: 10.1002/sim.3034]

18 **Köttgen A**, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, Pistis G, Ruggiero D, O'Seaghdha CM, Haller T, Yang Q, Tanaka T, Johnson AD, Kutalik Z, Smith AV, Shi J, Struchalin M, Middelberg RP, Brown MJ, Gaffo AL, Pirastu N, Li G, Hayward C, Zemunik T, Huffman J, Yengo L, Zhao JH, Demirkan A, Feitosa MF, Liu X, Malerba G, Lopez LM, van der Harst P, Li X, Kleber ME, Hicks AA, Nolte IM, Johansson A, Murgia F, Wild SH, Bakker SJ, Peden JF, Dehghan A, Steri M, Tenesa A, Lagou V, Salo P, Mangino M, Rose LM, Lehtimäki T, Woodward OM, Okada Y, Tin A, Müller C, Oldmeadow C, Putku M, Czamara D, Kraft P, Frogheri L, Thun GA, Grotevendt A, Gislason GK, Harris TB, Launer LJ, McArdle P, Shuldiner AR, Boerwinkle E, Coresh J, Schmidt H, Schallert M, Martin NG, Montgomery GW, Kubo M, Nakamura Y, Tanaka T, Munroe PB, Samani NJ, Jacobs DR Jr, Liu K, D'Adamo P, Ulivi S, Rotter JI, Psaty BM, Vollenweider P, Waeber G, Campbell S, Devuyst O, Navarro P, Kolcic I, Hastie N, Balkau B, Froguel P, Esko T, Salumets A, Khaw KT, Langenberg C, Wareham NJ, Isaacs A, Kraja A, Zhang Q, Wild PS, Scott RJ, Holliday EG, Org E, Viigimaa M, Bandinelli S, Metter JE, Lupo A, Trabetti E, Sorice R, Döring A, Lattka E, Strauch K, Theis F, Waldenberger M, Wichmann HE, Davies G, Gow AJ, Bruinenberg M; LifeLines Cohort Study, Stolk RP, Kooner JS, Zhang W, Winkelmann BR, Boehm BO, Lucae S, Penninx BW, Smit JH, Curhan G, Mudgal P, Plenge RM, Portas L, Persico I, Kirin M, Wilson JF, Mateo Leach I, van Gilst WH, Goel A, Ongen H, Hofman A, Rivadeneira F, Uitterlinden AG, Imboden M, von Eckardstein A, Cucca F, Nagaraja R, Piras MG, Nauck M, Schurmann C, Budde K, Ernst F, Farrington SM, Theodoratou E, Prokopenko I, Stumvoll M, Jula A, Perola M, Salomaa V, Shin SY, Spector TD, Sala C, Ridker PM, Kähönen M, Viikari J, Hengstenberg C, Nelson CP; CARDIoGRAM Consortium; DIAGRAM Consortium; ICBP Consortium; MAGIC Consortium, Meschia JF, Nalls MA, Sharma P, Singleton AB, Kamatani N, Zeller T, Burnier M, Attia J, Laan M, Klopp N, Hillege HL, Kloiber S, Choi H, Pirastu M, Tore S, Probst-Hensch NM, Völzke H, Gudnason V, Parsa A, Schmidt R, Whitfield JB, Fornage M, Gasparini P, Siscovick DS, Polašek O, Campbell H, Rudan I, Bouatia-Naji N, Metspalu A, Loos RJ, van Duijn CM, Borecki IB, Ferrucci L, Gambaro G, Deary IJ, Wolffenbuttel BH, Chambers JC, März W, Pramstaller PP, Snieder H, Gyllensten U, Wright AF, Navis G, Watkins H, Witteman JC, Sanna S, Schipf S, Dunlop MG, Tönjes A, Ripatti S, Soranzo N, Toniolo D, Chasman DI, Raitakari O, Kao WH, Ciullo M, Fox CS, Caulfield M, Bochud M, Gieger C. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. *Nat Genet* 2013; **45**: 145-154 [PMID: 23263486 DOI: 10.1038/ng.2500]

19 **Liu JZ**, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, Abedian S, Cheon JH, Cho J, Dayani NE, Franke L, Fuyuno Y, Hart A, Juyal RC, Juyal G, Kim WH, Morris AP, Poustchi H, Newman WG, Midha V, Orchard TR, Vahedi H, Sood A, Sung JY, Malekzadeh R, Westra HJ, Yamazaki K, Yang SK; International Multiple Sclerosis Genetics Consortium; International IBD Genetics Consortium, Barrett JC, Alizadeh BZ, Parkes M, Bk T, Daly MJ, Kubo M, Anderson CA, Weersma RK. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet* 2015; **47**: 979-986 [PMID: 26192919 DOI: 10.1038/ng.3359]

20 **Luo J**, Xu Z, Noordam R, van Heemst D, Li-Gao R. Depression and Inflammatory Bowel Disease: A Bidirectional Two-sample Mendelian Randomization Study. *J Crohns Colitis* 2022; **16**: 633-642 [PMID: 34739073 DOI: 10.1093/ecco-jcc/jjab191]

21 **Jiang L**, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for biobank-scale data. *Nat Genet* 2021; **53**: 1616-1621 [PMID: 34737426 DOI: 10.1038/s41588-021-00954-4]

22 **Burgess S**, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* 2013; **37**: 658-665 [PMID: 24114802 DOI: 10.1002/gepi.21758]

23 **Bowden J**, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* 2016; **40**: 304-314 [PMID: 27061298 DOI: 10.1002/gepi.21965]

24 **Bowden J**, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015; **44**: 512-525 [PMID: 26050253 DOI: 10.1093/ije/dyv080]

25 **Verbanck M**, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* 2018; **50**: 693-698 [PMID: 29686387 DOI: 10.1038/s41588-018-0099-7]

26 **Wirtz S**, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. *Nat Protoc* 2007; **2**: 541-546 [PMID: 17406617 DOI: 10.1038/nprot.2007.41]

27 **van Sommeren S**, Janse M, Karjalainen J, Fehrmann R, Franke L, Fu J, Weersma RK. Extraintestinal manifestations and complications in inflammatory bowel disease: from shared genetics to shared biological pathways. *Inflamm Bowel Dis* 2014; **20**: 987-994 [PMID: 24739630 DOI: 10.1097/MIB.0000000000000032]

28 **El-Mahdy NA**, Saleh DA, Amer MS, Abu-Risha SE. Role of allopurinol and febuxostat in the amelioration of dextran-induced colitis in rats. *Eur J Pharm Sci* 2020; **141**: 105116 [PMID: 31654756 DOI: 10.1016/j.ejps.2019.105116]

29 **Wu J**, Wei Z, Cheng P, Qian C, Xu F, Yang Y, Wang A, Chen W, Sun Z, Lu Y. Rhein modulates host purine metabolism in intestine through gut microbiota and ameliorates experimental colitis. *Theranostics* 2020; **10**: 10665-10679 [PMID: 32929373 DOI: 10.7150/thno.43528]

30 **Major TJ**, Topless RK, Dalbeth N, Merriman TR. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. *BMJ* 2018; **363**: k3951 [PMID: 30305269 DOI: 10.1136/bmj.k3951]

31 **Halmos EP**, Gibson PR. Dietary management of IBD--insights and advice. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 133-146 [PMID: 25645969 DOI: 10.1038/nrgastro.2015.11]

**Footnotes**

**Institutional review board statement:** The study did not include human trials.

**Institutional animal care and use committee statement:** All animal experimental procedures were approved and conducted in accordance with the guidelines of the Animal Care Committee of Navy Medical University (CHEC(A.E.)2023-046).

**Informed consent statement:** All data used in the current manuscript was available online, thus the Signed Informed Consent Form(s) or Document(s) was not applied for the current manuscript.

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Data sharing statement:** The data underlying this article are available in individual referenced papers, the Finngen database (https://r7.finngen.fi/) and the IEU OpenGWAS project (https://gwas.mrcieu.ac.uk/).

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 9, 2023

**First decision:** December 14, 2023

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Vaishalli PM, India **S-Editor:** Fan JR **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 Overview of study design.** IBD: Inflammatory bowel disease; SNP: Single-nucleotide polymorphisms; UC: Ulcerative colitis; CD: Crohn’s disease; UA: Ursolic acid; MR: Mendelian randomization.



**Figure 2 Association of urate levels and inflammatory bowel disease in Mendelian randomization analyses (inverse-variance weighted estimate).** Estimated odds ratios (OR) represent the effect of per log-OR increase in urate levels on inflammatory bowel disease (IBD), using inverse-variance weighted analysis, per outcome database separately. The meta-analyses combined the three databases (genome-wide association studies meta-analysis by Liu *et al*[19] and the FinnGen and UK Biobank databases) for UC and the former two databases for IBD and Crohn’s disease (UK Biobank data were not available) using a fixed-effects model. IBD: Inflammatory bowel disease; UA: Ursolic acid; UC: Ulcerative colitis; SNP: Single-nucleotide polymorphisms; CD: Crohn’s disease; CI: Confidence interval; IVW: Inverse-variance weighted.



**Figure 3 Scatter plot of Mendelian randomization analyses from urate levels to inflammatory bowel disease in each database.** The X-axes indicate the single-nucleotide polymorphisms (SNPs) of urate levels, while the Y-axes indicate the SNPs of inflammatory bowel disease from different outcome databases. The black dots represent the genetic instruments included in the current Mendelian randomization (MR) analyses. The five colors represent five different genetic estimates: Red: Inverse-variance weighted; Blue: Weighted-median estimator; Green: MR Egger. IBD: Inflammatory bowel disease; SNP: Single-nucleotide polymorphisms.



**Figure 4 Association of inflammatory bowel disease and urate levels in Mendelian randomization analyses (inverse-variance weighted estimate).** Estimated odds ratio (OR) represent the effect of per log-OR increase in inflammatory bowel disease on urate levels, using inverse-variance weighted analysis with a fixed-effects model. IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; CI: Confidence interval; SNP: Single-nucleotide polymorphisms; UA: Ursolic acid; IVW: Inverse-variance weighted.



**Figure 5 Scatter plot of the association of inflammatory bowel disease with urate levels.** The detailed description is the same as in Figure 3. IBD: Inflammatory bowel disease; SNP: Single-nucleotide polymorphisms.

 

**Figure 6 Dextran sulfate sodium contributed to increase of inflammation in inflammatory bowel disease mice.** C57BL/6 mice were administered dextran sulfate sodium (DSS) (2%) for 7 d (and a control group was provided with water only for comparison) and 2 d for water. A-E: DSS group (*n* = 5) exhibited a significant aggravation of inflammatory bowel disease-associated changes in of body weight (A), disease activity index (B), colon length (C), inflammatory infiltration (D) and increased levels of interleukin (IL)-6, IL-1β and tumor necrosis factor-α (E); F: Compared with control group (*n* = 5), DSS group demonstrated increased levels of urate levels. DSS: Dextran sulfate sodium; NC: Control group; IL: Interleukin; TNF: Tumor necrosis factor; DAI: Disease activity index. a*P* < 0.05; b*P* < 0.01; c*P* < 0.001.